<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>News</title>
    <link>https://ionetix.com/news</link>
    <description>News</description>
    <language>en</language>
    <pubDate>Fri, 13 Nov 2026 17:04:59 GMT</pubDate>
    <dc:date>2026-11-13T17:04:59Z</dc:date>
    <dc:language>en</dc:language>
    <item>
      <title>Ionetix Begins Shipping Astatine-211 to Support Preclinical and Clinical Trials - Ionetix</title>
      <link>https://ionetix.com/news/ionetix-begins-shipping-astatine-211-to-support-preclinical-and-clinical-trials</link>
      <description>&lt;p&gt;&lt;em&gt;– New North American supply addresses a key barrier to advancing targeted alpha therapy –&lt;/em&gt;&lt;/p&gt;</description>
      <content:encoded>&lt;p&gt;&lt;em&gt;– New North American supply addresses a key barrier to advancing targeted alpha therapy –&lt;/em&gt;&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=19944240&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fionetix.com%2Fnews%2Fionetix-begins-shipping-astatine-211-to-support-preclinical-and-clinical-trials&amp;amp;bu=https%253A%252F%252Fionetix.com%252Fnews&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <pubDate>Tue, 01 Sep 2026 05:00:00 GMT</pubDate>
      <guid>https://ionetix.com/news/ionetix-begins-shipping-astatine-211-to-support-preclinical-and-clinical-trials</guid>
      <dc:date>2026-09-01T05:00:00Z</dc:date>
      <dc:creator>Admin</dc:creator>
    </item>
    <item>
      <title>Ionetix Announces Approval of Abbreviated New Drug Application for Gallium Ga-68 Gozetotide (PSMA-11)</title>
      <link>https://ionetix.com/news/2026/05/26/ionetix-announcement-approval-of-abbreviated-new-drug-application-for-gallium-ga-68-gozetotide-psma-11</link>
      <description>&lt;p style="text-align: left"&gt;&lt;i&gt;Leading particle accelerator company expands portfolio of positron emission tomography&lt;/i&gt; &lt;em&gt;diagnostics&lt;/em&gt;&lt;/p&gt;</description>
      <content:encoded>&lt;p style="text-align: left"&gt;&lt;i&gt;Leading particle accelerator company expands portfolio of positron emission tomography&lt;/i&gt; &lt;em&gt;diagnostics&lt;/em&gt;&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=19944240&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fionetix.com%2Fnews%2F2026%2F05%2F26%2Fionetix-announcement-approval-of-abbreviated-new-drug-application-for-gallium-ga-68-gozetotide-psma-11&amp;amp;bu=https%253A%252F%252Fionetix.com%252Fnews&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <pubDate>Tue, 26 May 2026 05:00:00 GMT</pubDate>
      <guid>https://ionetix.com/news/2026/05/26/ionetix-announcement-approval-of-abbreviated-new-drug-application-for-gallium-ga-68-gozetotide-psma-11</guid>
      <dc:date>2026-05-26T05:00:00Z</dc:date>
      <dc:creator>Admin</dc:creator>
    </item>
    <item>
      <title>Ionetix Completes $30 million+ Financing in a Go-Public Transaction</title>
      <link>https://ionetix.com/news/2026/04/21/ionetix-completes-30-million-financing-in-a-go-public-transaction</link>
      <description>&lt;p&gt;&lt;em&gt;Leading Particle Accelerator company expanding production capacity to produce medical isotopes and increase R&amp;amp;D capabilities in other verticals&lt;/em&gt;&lt;/p&gt;</description>
      <content:encoded>&lt;p&gt;&lt;em&gt;Leading Particle Accelerator company expanding production capacity to produce medical isotopes and increase R&amp;amp;D capabilities in other verticals&lt;/em&gt;&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=19944240&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fionetix.com%2Fnews%2F2026%2F04%2F21%2Fionetix-completes-30-million-financing-in-a-go-public-transaction&amp;amp;bu=https%253A%252F%252Fionetix.com%252Fnews&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <pubDate>Tue, 21 Apr 2026 05:00:00 GMT</pubDate>
      <guid>https://ionetix.com/news/2026/04/21/ionetix-completes-30-million-financing-in-a-go-public-transaction</guid>
      <dc:date>2026-04-21T05:00:00Z</dc:date>
      <dc:creator>Admin</dc:creator>
    </item>
    <item>
      <title>Ionetix Invests $25.75M in Delta Township Facility, Creating 53 High-Tech Jobs and Advancing Lansing’s MedTech Leadership</title>
      <link>https://ionetix.com/news/ionetix-invests-25.75m-in-delta-township-facility-creating-53-high-tech-jobs-and-advancing-lansings-medtech-leadership</link>
      <description>&lt;p&gt;LANSING, Mich. – Ionetix, a leader in advanced radiopharmaceutical technologies, is investing $25.75 million to expand its Delta Township facility. The project will add a second cyclotron, and an advanced isotope processing laboratory. The expansion is expected to create 53 high-tech jobs and further accelerate innovation in life sciences and nuclear medicine manufacturing.&lt;br&gt;&lt;br&gt;“Ionetix’s expansion is creating high-skill, high-value jobs and elevating the Lansing Region within the global medical technology landscape,” said Bob Trezise, president and CEO of the Lansing Economic Area Partnership (LEAP). “LEAP is proud to support this project and the ecosystem of innovative MedTech companies making our region a destination for biomedical research and economic opportunity.”&lt;br&gt;&lt;br&gt;Ionetix marked the milestone with a community event at its Delta Township facility, bringing together company leaders, regional partners, and officials from across the state. Speakers included representatives from Ionetix, LEAP, the Michigan Economic Development Corporation (MEDC), and Delta Township.&lt;br&gt;&lt;br&gt;Founded in 2009 from technology developed at the MIT Plasma Science and Fusion Center, Ionetix has pioneered the world’s first commercial compact superconducting cyclotron, the ION-12SC, which is used to produce N-13 ammonia, one of the most accurate positron emission tomography (PET) imaging agents for detecting coronary artery disease (CAD). The company has also expanded its focus to targeted alpha therapy (TAT), an emerging cancer treatment utilizing high-energy alpha particles to target cancer cells while preserving healthy tissue.&lt;br&gt;&lt;br&gt;“Delta Township and the Lansing region offer the ideal environment for Ionetix’s continued growth. The area’s highly skilled workforce, robust infrastructure, and strong spirit of public-private collaboration make it the perfect location for our expansion,” said Kevin J. Cameron, Chief Executive Officer of Ionetix. “We are honored to invest in this community and proud that it is in the forefront of creating diagnostic and therapeutic innovations.”&lt;br&gt;&lt;br&gt;This expansion aligns with IIonetix’s broader strategy to grow its radiopharmaceutical manufacturing network, advance commercialization of new therapies, and reinforce Michigan’s leadership in life sciences and medical technology innovation.&lt;br&gt;&lt;br&gt;The State of Michigan, through the Michigan Business Development Program, awarded Ionetix $750,000 in incentives to support this expansion, ensuring a strong pipeline of skilled talent and continued innovation in the region.&lt;br&gt;&lt;br&gt;We are thrilled with the company’s commitment to Michigan and the Lansing community by investing over $25 million to accelerate the efforts to one day cure cancer,” said Matt McCauley, Senior Vice President for Regional Development at the MEDC. “Team Michigan welcomes Ionetix Corporation’s expansion, furthering Michigan’s leadership in the life sciences and medical technology industries. We applaud the company’s vision to Make it in Michigan.&lt;br&gt;&lt;br&gt;The Ionetix expansion reinforces Michigan’s strength in radiopharmaceutical innovation, building on Michigan State University’s no. 2 national ranking in nuclear physics and robust network of MedTech and life sciences companies across the region.&lt;br&gt;&lt;br&gt;“Delta Township is proud to support Ionetix’s continued growth and the incredible impact this expansion will have on our local economy,” said Fonda Brewer, Delta Township Supervisor. “This investment not only brings dozens of high-tech, high-paying jobs to our community, but also solidifies Delta Township as a destination for cutting-edge MedTech innovation. We look forward to supporting IONETIX and the broader growth of Michigan’s life sciences sector.”&lt;br&gt;&lt;br&gt;The addition of Ionetix to Michigan’s Health Core—a regional coalition of life sciences, healthcare, and technology leaders based in the Lansing Region—reaffirms the state’s position as a national leader in medical technology innovation.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;About Ionetix&lt;br&gt;Utilizing its proprietary cyclotron technology platform, Ionetix has developed innovative solutions that enable access to scarce radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. Ionetix offers both high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies.  Ionetix also provides N-13, F-18 and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and “white glove” distribution logistics, allowing global access to these imaging agents and targeted radiotherapies. Contact us for more information.&lt;/p&gt;</description>
      <content:encoded>&lt;p&gt;LANSING, Mich. – Ionetix, a leader in advanced radiopharmaceutical technologies, is investing $25.75 million to expand its Delta Township facility. The project will add a second cyclotron, and an advanced isotope processing laboratory. The expansion is expected to create 53 high-tech jobs and further accelerate innovation in life sciences and nuclear medicine manufacturing.&lt;br&gt;&lt;br&gt;“Ionetix’s expansion is creating high-skill, high-value jobs and elevating the Lansing Region within the global medical technology landscape,” said Bob Trezise, president and CEO of the Lansing Economic Area Partnership (LEAP). “LEAP is proud to support this project and the ecosystem of innovative MedTech companies making our region a destination for biomedical research and economic opportunity.”&lt;br&gt;&lt;br&gt;Ionetix marked the milestone with a community event at its Delta Township facility, bringing together company leaders, regional partners, and officials from across the state. Speakers included representatives from Ionetix, LEAP, the Michigan Economic Development Corporation (MEDC), and Delta Township.&lt;br&gt;&lt;br&gt;Founded in 2009 from technology developed at the MIT Plasma Science and Fusion Center, Ionetix has pioneered the world’s first commercial compact superconducting cyclotron, the ION-12SC, which is used to produce N-13 ammonia, one of the most accurate positron emission tomography (PET) imaging agents for detecting coronary artery disease (CAD). The company has also expanded its focus to targeted alpha therapy (TAT), an emerging cancer treatment utilizing high-energy alpha particles to target cancer cells while preserving healthy tissue.&lt;br&gt;&lt;br&gt;“Delta Township and the Lansing region offer the ideal environment for Ionetix’s continued growth. The area’s highly skilled workforce, robust infrastructure, and strong spirit of public-private collaboration make it the perfect location for our expansion,” said Kevin J. Cameron, Chief Executive Officer of Ionetix. “We are honored to invest in this community and proud that it is in the forefront of creating diagnostic and therapeutic innovations.”&lt;br&gt;&lt;br&gt;This expansion aligns with IIonetix’s broader strategy to grow its radiopharmaceutical manufacturing network, advance commercialization of new therapies, and reinforce Michigan’s leadership in life sciences and medical technology innovation.&lt;br&gt;&lt;br&gt;The State of Michigan, through the Michigan Business Development Program, awarded Ionetix $750,000 in incentives to support this expansion, ensuring a strong pipeline of skilled talent and continued innovation in the region.&lt;br&gt;&lt;br&gt;We are thrilled with the company’s commitment to Michigan and the Lansing community by investing over $25 million to accelerate the efforts to one day cure cancer,” said Matt McCauley, Senior Vice President for Regional Development at the MEDC. “Team Michigan welcomes Ionetix Corporation’s expansion, furthering Michigan’s leadership in the life sciences and medical technology industries. We applaud the company’s vision to Make it in Michigan.&lt;br&gt;&lt;br&gt;The Ionetix expansion reinforces Michigan’s strength in radiopharmaceutical innovation, building on Michigan State University’s no. 2 national ranking in nuclear physics and robust network of MedTech and life sciences companies across the region.&lt;br&gt;&lt;br&gt;“Delta Township is proud to support Ionetix’s continued growth and the incredible impact this expansion will have on our local economy,” said Fonda Brewer, Delta Township Supervisor. “This investment not only brings dozens of high-tech, high-paying jobs to our community, but also solidifies Delta Township as a destination for cutting-edge MedTech innovation. We look forward to supporting IONETIX and the broader growth of Michigan’s life sciences sector.”&lt;br&gt;&lt;br&gt;The addition of Ionetix to Michigan’s Health Core—a regional coalition of life sciences, healthcare, and technology leaders based in the Lansing Region—reaffirms the state’s position as a national leader in medical technology innovation.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;About Ionetix&lt;br&gt;Utilizing its proprietary cyclotron technology platform, Ionetix has developed innovative solutions that enable access to scarce radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. Ionetix offers both high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies.  Ionetix also provides N-13, F-18 and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and “white glove” distribution logistics, allowing global access to these imaging agents and targeted radiotherapies. Contact us for more information.&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=19944240&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fionetix.com%2Fnews%2Fionetix-invests-25.75m-in-delta-township-facility-creating-53-high-tech-jobs-and-advancing-lansings-medtech-leadership&amp;amp;bu=https%253A%252F%252Fionetix.com%252Fnews&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <pubDate>Mon, 16 Jun 2025 05:00:00 GMT</pubDate>
      <guid>https://ionetix.com/news/ionetix-invests-25.75m-in-delta-township-facility-creating-53-high-tech-jobs-and-advancing-lansings-medtech-leadership</guid>
      <dc:date>2025-06-16T05:00:00Z</dc:date>
      <dc:creator>Ionetix</dc:creator>
    </item>
    <item>
      <title>Ionetix Launches Commercial Actinium-225 Production | Ac-225</title>
      <link>https://ionetix.com/news/2024/06/07/ionetix-produces-first-batch-of-actinium-225</link>
      <description>&lt;p&gt;&lt;em&gt;&lt;span class="legendSpanClass"&gt;&lt;span class="xn-location"&gt;LANSING, Mich.&lt;/span&gt;&lt;/span&gt;,&amp;nbsp;&lt;span class="legendSpanClass"&gt;&lt;span class="xn-chron"&gt;June 7, 2024&lt;/span&gt;&lt;/span&gt;&amp;nbsp;&lt;/em&gt;— IONETIX, a leading cyclotron technology innovator, isotope producer, and radiopharmaceutical manufacturer, announced today the successful production of Actinium-225 (“Ac-225”) at its isotope manufacturing facility located in &lt;span class="xn-location"&gt;Lansing, Michigan&lt;/span&gt;.&lt;/p&gt;</description>
      <content:encoded>&lt;p&gt;&lt;em&gt;&lt;span class="legendSpanClass"&gt;&lt;span class="xn-location"&gt;LANSING, Mich.&lt;/span&gt;&lt;/span&gt;,&amp;nbsp;&lt;span class="legendSpanClass"&gt;&lt;span class="xn-chron"&gt;June 7, 2024&lt;/span&gt;&lt;/span&gt;&amp;nbsp;&lt;/em&gt;— IONETIX, a leading cyclotron technology innovator, isotope producer, and radiopharmaceutical manufacturer, announced today the successful production of Actinium-225 (“Ac-225”) at its isotope manufacturing facility located in &lt;span class="xn-location"&gt;Lansing, Michigan&lt;/span&gt;.&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=19944240&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fionetix.com%2Fnews%2F2024%2F06%2F07%2Fionetix-produces-first-batch-of-actinium-225&amp;amp;bu=https%253A%252F%252Fionetix.com%252Fnews&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <pubDate>Fri, 07 Jun 2024 05:00:00 GMT</pubDate>
      <guid>https://ionetix.com/news/2024/06/07/ionetix-produces-first-batch-of-actinium-225</guid>
      <dc:date>2024-06-07T05:00:00Z</dc:date>
      <dc:creator>Admin</dc:creator>
    </item>
    <item>
      <title>Ionetix announces appointment of Douglas Boothe to Board of Directors - Ionetix</title>
      <link>https://ionetix.com/news/2024/03/26/ionetix-announces-appointment-of-douglas-boothe-to-board-of-directors</link>
      <description>&lt;p&gt;&lt;strong&gt;March 26, 2024,&lt;/strong&gt; &lt;strong&gt;Lansing MI – &lt;/strong&gt;IONETIX, a leading cyclotron technology and isotope manufacturing company, is pleased to announce the appointment of Douglas Boothe to its Board of Directors. Mr. Boothe currently serves as CEO at Edenbridge Pharmaceuticals and brings over 30 years of leadership skills and proven business results in pharmaceutical sales, marketing, operations, business development, and regulatory to IONETIX. “Doug’s deep pharmaceutical expertise and proven track record aligns well with our growth strategy and will help guide IONETIX at this pivotal time for the company.” said Kevin Cameron, Chairman of IONETIX. Boothe noted, “I am excited to join IONETIX at such a dynamic time for both the company and the radiopharmaceutical space broadly. I look forward to helping the team through what promises to be a period of significant growth.”&lt;/p&gt;</description>
      <content:encoded>&lt;p&gt;&lt;strong&gt;March 26, 2024,&lt;/strong&gt; &lt;strong&gt;Lansing MI – &lt;/strong&gt;IONETIX, a leading cyclotron technology and isotope manufacturing company, is pleased to announce the appointment of Douglas Boothe to its Board of Directors. Mr. Boothe currently serves as CEO at Edenbridge Pharmaceuticals and brings over 30 years of leadership skills and proven business results in pharmaceutical sales, marketing, operations, business development, and regulatory to IONETIX. “Doug’s deep pharmaceutical expertise and proven track record aligns well with our growth strategy and will help guide IONETIX at this pivotal time for the company.” said Kevin Cameron, Chairman of IONETIX. Boothe noted, “I am excited to join IONETIX at such a dynamic time for both the company and the radiopharmaceutical space broadly. I look forward to helping the team through what promises to be a period of significant growth.”&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=19944240&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fionetix.com%2Fnews%2F2024%2F03%2F26%2Fionetix-announces-appointment-of-douglas-boothe-to-board-of-directors&amp;amp;bu=https%253A%252F%252Fionetix.com%252Fnews&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <pubDate>Tue, 26 Mar 2024 05:00:00 GMT</pubDate>
      <guid>https://ionetix.com/news/2024/03/26/ionetix-announces-appointment-of-douglas-boothe-to-board-of-directors</guid>
      <dc:date>2024-03-26T05:00:00Z</dc:date>
      <dc:creator>Admin</dc:creator>
    </item>
  </channel>
</rss>
